Farallon Capital Management Has Increased Its Sage Therapeutics (SAGE) Holding; Achaogen (AKAO)’s Sentiment Is 1.16

January 14, 2018 - By Adrian Erickson

Farallon Capital Management Llc increased Sage Therapeutics Inc (SAGE) stake by 143.5% reported in 2017Q3 SEC filing. Farallon Capital Management Llc acquired 143,500 shares as Sage Therapeutics Inc (SAGE)’s stock rose 0.86%. The Farallon Capital Management Llc holds 243,500 shares with $15.17 million value, up from 100,000 last quarter. Sage Therapeutics Inc now has $7.22 billion valuation. The stock increased 0.72% or $1.26 during the last trading session, reaching $175.86. About 323,490 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 116.45% since January 14, 2017 and is uptrending. It has outperformed by 99.75% the S&P500.

Achaogen, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant gram-negative infections in the United States. The company has market cap of $506.18 million. The firm is principally developing plazomicin, which is in Phase III clinical trial for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR Enterobacteriaceae comprising carbapenem-resistant Enterobacteriaceae. It currently has negative earnings. It is also involved in the research and development of antipseudomonal LpxC inhibitor compounds for the treatment of bacterial infections; and therapeutic antibody discovery program.

Nea Management Company Llc holds 2.91% of its portfolio in Achaogen, Inc. for 5.22 million shares. Emory University owns 100,821 shares or 1.27% of their US portfolio. Moreover, University Of Notre Dame Du Lac has 0.69% invested in the company for 155,654 shares. The New York-based Baker Bros. Advisors Lp has invested 0.5% in the stock. Polar Capital Llp, a United Kingdom-based fund reported 1.90 million shares.

Ratings analysis reveals 100% of Achaogen’s analysts are positive. Out of 5 Wall Street analysts rating Achaogen, 5 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $19.0 while the high is $27.0. The stock’s average target of $23 is 92.63% above today’s ($11.94) share price. AKAO was included in 5 notes of analysts from November 2, 2016. The stock has “Buy” rating by Needham on Tuesday, December 13. The company was maintained on Wednesday, February 1 by Wedbush. The firm has “Buy” rating given on Wednesday, November 2 by Aegis Capital. The firm has “Outperform” rating given on Wednesday, January 4 by Leerink Swann. Stifel Nicolaus initiated the stock with “Buy” rating in Tuesday, February 7 report.

Since January 1, 0001, it had 2 insider buys, and 2 selling transactions for $1.72 million activity.

The stock decreased 3.86% or $0.48 during the last trading session, reaching $11.94. About 1.36M shares traded or 29.57% up from the average. Achaogen, Inc. (AKAO) has risen 757.99% since January 14, 2017 and is uptrending. It has outperformed by 741.29% the S&P500.

Analysts await Achaogen, Inc. (NASDAQ:AKAO) to report earnings on March, 13. They expect $-0.79 EPS, up 24.04% or $0.25 from last year’s $-1.04 per share. After $-0.85 actual EPS reported by Achaogen, Inc. for the previous quarter, Wall Street now forecasts -7.06% EPS growth.

Investors sentiment increased to 1.21 in Q3 2017. Its up 0.23, from 0.98 in 2017Q2. It is positive, as 33 investors sold SAGE shares while 43 reduced holdings. 28 funds opened positions while 64 raised stakes. 38.55 million shares or 3.62% more from 37.20 million shares in 2017Q2 were reported. University Of Notre Dame Du Lac invested in 0.52% or 30,144 shares. Hershey Tru Company holds 0% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 1,887 shares. American Century, Missouri-based fund reported 25,343 shares. Tiaa Cref Investment Management has invested 0.01% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Group Inc invested in 23,174 shares. Credit Suisse Ag holds 0% or 77,977 shares. Tradewinds Capital Mngmt Llc holds 0% or 137 shares. Oppenheimer Asset Mngmt Inc reported 1,944 shares. Emerald Mutual Fund Advisers Tru holds 0.16% or 62,708 shares in its portfolio. Vanguard Gp Incorporated Inc has invested 0.01% in Sage Therapeutics, Inc. (NASDAQ:SAGE). United Kingdom-based Pictet Asset Mngmt Limited has invested 0.07% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Cutter Brokerage Incorporated reported 5,226 shares. Gam Hldg Ag has invested 0.21% in Sage Therapeutics, Inc. (NASDAQ:SAGE). The Washington-based Parametric Associates has invested 0% in Sage Therapeutics, Inc. (NASDAQ:SAGE). Comml Bank Of America Corp De holds 0% of its portfolio in Sage Therapeutics, Inc. (NASDAQ:SAGE) for 100,312 shares.

Farallon Capital Management Llc decreased Charter Communications Inc N stake by 143,570 shares to 191,255 valued at $69.51M in 2017Q3. It also reduced Sba Communications Corp New stake by 924,231 shares and now owns 136,738 shares. Ryanair Hldgs Plc was reduced too.

Since December 14, 2017, it had 0 insider buys, and 1 sale for $9.57 million activity. Shares for $9.57M were sold by Robichaud Albert on Thursday, December 14.

Among 17 analysts covering SAGE Therapeutics (NASDAQ:SAGE), 15 have Buy rating, 0 Sell and 2 Hold. Therefore 88% are positive. SAGE Therapeutics had 51 analyst reports since September 3, 2015 according to SRatingsIntel. The rating was maintained by Cowen & Co on Tuesday, September 12 with “Buy”. BMO Capital Markets maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) on Thursday, November 9 with “Buy” rating. The company was maintained on Monday, October 16 by RBC Capital Markets. As per Thursday, August 3, the company rating was maintained by Cowen & Co. The rating was maintained by RBC Capital Markets on Thursday, November 9 with “Buy”. The stock of Sage Therapeutics, Inc. (NASDAQ:SAGE) has “Sell” rating given on Tuesday, May 24 by Chardan Capital Markets. The stock has “Buy” rating by Canaccord Genuity on Tuesday, September 12. Leerink Swann maintained the stock with “Buy” rating in Thursday, December 7 report. BMO Capital Markets maintained Sage Therapeutics, Inc. (NASDAQ:SAGE) rating on Thursday, September 14. BMO Capital Markets has “Outperform” rating and $80 target. The firm earned “Buy” rating on Monday, November 14 by Stifel Nicolaus.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

>